Partnership will Enable Accuray to Use Limbus'
Technology to Streamline the Treatment Planning Process and
Increase Operational Efficiency
SUNNYVALE, Calif. and SASKATCHEWAN, Canada, June 2, 2022
/PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Limbus AI
Inc. announced today they are partnering to augment Accuray
adaptive radiotherapy capabilities by leveraging Limbus' artificial
intelligence (AI)-driven autocontouring algorithms - enabling
automated contouring to further streamline the treatment planning
process*. The companies expect an integrated offering to be made
available beginning in 2023.
Changes in tumor size, shape and location, or in the position of
organs and other healthy tissue due to weight gain or loss during
the course of radiation therapy, may require adaptation of the
treatment plan to ensure the radiation dose remains targeted on the
tumor while avoiding nearby sensitive organs. Modifications to
plans as part of the adaptive workflow, however, can be
prohibitively time consuming and labor intensive. Contouring –
defining the border of the tumor and organs at risk – is one of the
most critical steps in the planning process and accounts for a
significant proportion of both the personnel and time involved in
plan adaptation.
Automating the contouring portion of the overall planning
process opens the door to practical adaptive plan modification,
when warranted, for any patient undergoing treatment, without
overwhelming already stretched clinical staff. High-quality
automation tools such as the one developed by Limbus AI for
contouring also make it easier for medical care teams to ensure
consistency in the plans created.
"Accuray is focused on improving the care of patients undergoing
radiation therapy. Providing practical adaptive solutions for
clinics of any size, in any location, is one approach and the
software offered by Limbus AI will play a big role in making this
goal a reality," said Joshua H.
Levine, chief executive officer of Accuray. "The partnership
with Limbus represents another step forward for Accuray in the
development of innovative artificial intelligence (AI)-driven
solutions that meet the needs of providers and enables them to
deliver personalized patient care, such as with our
Synchrony® AI-driven real-time target tracking with
dynamic delivery technology, on both the Radixact® and
CyberKnife® Systems."
"We're thrilled to be working closely with the Accuray team to
bring our AI models directly to the treatment machine, where
accuracy and efficiency are critical to providing the best patient
care. Both companies are focused on providing the best tools to
clinicians to enhance radiotherapy treatment delivery," said Dr.
Joshua Giambattista, CEO and Medical
Director of Limbus AI. "We are confident that our AI models will
continue to set the standard for automatic contouring for all
treatment plans, including those used in adaptive therapy. This
technology will improve efficiency for clinicians, enabling
optimal treatment planning in a shorter period of time. These
advances will expand utilization of treatment machines so more
patients can receive state of the art care."
*Works in progress.
About Limbus AI Inc.
At Limbus AI Inc., our passionate team of healthcare and
technology specialists is dedicated to improving cancer care
through the development of state-of-the-art software. Our machine
learning based products improve efficiency and clinical workflows
in cancer radiation treatment planning. We specialize in the
creation of artificial intelligence (AI)-driven automatic
contouring algorithms performed entirely on customers' existing
clinical workstations within the security of their own local
network. These unique software solutions enable clinicians to more
quickly create more accurate treatment plans, allowing for the
delivery of more precise treatments throughout the course of
care. Limbus AI is headquartered in Regina Saskatchewan, Canada. To learn
more, visit www.limbus.ai or follow us on LinkedIn and Twitter.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations related to the
timing and impact of Accuray's relationship with Limbus, clinical
applications, clinical results, patient experiences and outcomes.
If any of these risks or uncertainties materialize, or if any of
the company's assumptions prove incorrect, actual results could
differ materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the effect of the COVID-19 pandemic on the
operations of the company and those of its customers and suppliers;
disruptions to our supply chain, including increased logistics
costs; the company's ability to achieve widespread market
acceptance of its products, including new product and software
offerings; the company's ability to develop new products or enhance
existing products to meet customers' needs and compete favorably in
the market; delays in regulatory approvals or the development or
release of new offerings; the company's ability to meet the
covenants under its credit facilities; the company's ability to
convert backlog to revenue; and such other risks identified under
the heading "Risk Factors" in the company's Quarterly Report on
Form 10-Q, filed with the Securities and Exchange Commission (the
"SEC") on April 29, 2022 and as
updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
For further information about Limbus AI Inc.:
David Talton
VP Sales, Marketing and Business Development, Limbus AI
+1 (215) 431-5679
dave@limbus.ai
For further information about Accuray
Incorporated:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-and-limbus-ai-inc-partner-to-leverage-limbus-innovative-ai-driven-technology-to-enhance-accuray-adaptive-radiotherapy-solutions-301559886.html
SOURCE Accuray Incorporated